Sinclair Dunlop - Jun 28, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Stock symbol
APLS
Transactions as of
Jun 28, 2024
Transactions value $
$11,871
Form type
4
Date filed
7/1/2024, 04:02 PM
Previous filing
Jun 21, 2024
Next filing
Sep 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $11.9K +900 +0.67% $13.19 134K Jun 28, 2024 Direct
holding APLS Common Stock 137K Jun 28, 2024 Indirect Owner (Epidarex) F1
holding APLS Common Stock 31.9K Jun 28, 2024 Indirect Owner (Masa) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -900 -16.36% $0.00 4.6K Jun 28, 2024 Common Stock 900 $13.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F2 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
F3 This option was granted on January 1, 2019 and fully vested.